Research Unravels New Ways to Treat HER2-Positive Breast Cancer
New therapies and combinations make progress in HER2-positive breast cancer.
Read More
Joanna Montgomery's video story: It's Cancer, Baby
Is a digital pill to track medical adherence in your future?
Jake Gibb: Olympian, testicular cancer survivor
Pancreatic Cancer Action Network pushes for legislation after the passing of Sally Ride
Sally Ride: pancreatic cancer survivor
A video tour before your treatment?
Stand Up to Cancer hosts third fundraising telecast
Be The Match offers transplant survivors post-care guidelines
LIVESTRONG offers parenting with cancer class
First Steps: Vaccine Research
Research into vaccine therapy for cancer is extending to many cancer types.
Long-Term Estrogen-Only Hormone Therapy Increases Breast Cancer Risk
Estrogen-only hormone therapy ups breast cancer risk if taken long term.
‘Super Herceptin’ Excels in HER2 Breast Cancer
Data from the phase 3 EMILIA trial shows progression-free survival benefit in metastatic HER2-positive breast cancer patients.
Avastin Produces Results in Chemo-Resistant Ovarian Cancer
To tackle platinum-resistant ovarian cancer, a French research group added Avastin (bevacizumab) to standard chemotherapy.
Investigational Drug Effective in Treating Resistant GIST, Colorectal Cancer
Regorafenib, which targets two cancer cell pathways, extended survival in both cancers in two separate studies for GIST and metastatic colorectal cancer.
HPV status in head and neck cancer may affect treatment decisions
Avastin and olaparib may get a second chance in ovarian cancers
Reconstruction decisions
ASCO 2012 ... the latest in cancer research
Regorafenib available in expanded access program for colon cancer
Organ donation and cancer survivors
YouTube plea helps patient get breast cancer drug early
Photo slideshow: Children are caregivers, inspiration
Boston Marathon: Thinking of Ed and Sarah
Dental health Facebook chat: A recap
Do you need a baseline mammogram?
Whole genome sequencing: The benefit and burden of knowing all of your genetic risks
Entering the consumer genome era
The state of cancer research
First Descents opens new programs, looks for medical volunteers